Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Double-Blind Placebo-Controlled Study of Oral BLD-2660 in Idiopathic Pulmonary Fibrosis
2019-004998-34Phase 2Terminated
- Sponsor
- Blade Therapeutics, Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BLD-2660 with Placebo (2 arms). Primary endpoint: Primary pharmacokinetic endpoints. Started Feb 2020; status: terminated.
02
Drugs
dazcapistat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2019-004998-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004998-34.